JP2017516752A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516752A5
JP2017516752A5 JP2016559997A JP2016559997A JP2017516752A5 JP 2017516752 A5 JP2017516752 A5 JP 2017516752A5 JP 2016559997 A JP2016559997 A JP 2016559997A JP 2016559997 A JP2016559997 A JP 2016559997A JP 2017516752 A5 JP2017516752 A5 JP 2017516752A5
Authority
JP
Japan
Prior art keywords
peptide
acid sequence
seq
amino acid
sdvgeyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016559997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/057258 external-priority patent/WO2015150492A2/en
Publication of JP2017516752A publication Critical patent/JP2017516752A/ja
Publication of JP2017516752A5 publication Critical patent/JP2017516752A5/ja
Ceased legal-status Critical Current

Links

JP2016559997A 2014-04-01 2015-04-01 単離されたドナーmhc由来ペプチド及びその使用 Ceased JP2017516752A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163072.3 2014-04-01
EP14163072 2014-04-01
PCT/EP2015/057258 WO2015150492A2 (en) 2014-04-01 2015-04-01 An isolated donor mhc-derived peptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019219658A Division JP2020055844A (ja) 2014-04-01 2019-12-04 単離されたドナーmhc由来ペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2017516752A JP2017516752A (ja) 2017-06-22
JP2017516752A5 true JP2017516752A5 (enExample) 2018-03-01

Family

ID=50390009

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016559997A Ceased JP2017516752A (ja) 2014-04-01 2015-04-01 単離されたドナーmhc由来ペプチド及びその使用
JP2019219658A Pending JP2020055844A (ja) 2014-04-01 2019-12-04 単離されたドナーmhc由来ペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019219658A Pending JP2020055844A (ja) 2014-04-01 2019-12-04 単離されたドナーmhc由来ペプチド及びその使用

Country Status (5)

Country Link
US (1) US10137181B2 (enExample)
EP (2) EP3126374B1 (enExample)
JP (2) JP2017516752A (enExample)
ES (1) ES2702676T3 (enExample)
WO (1) WO2015150492A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6916746B2 (ja) 2015-07-03 2021-08-11 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) 制御性t細胞を得る方法およびその使用
CN108291203A (zh) * 2015-09-07 2018-07-17 国家健康科学研究所 Cd8+cd45rc低treg的新亚群及其用途
CR20180530A (es) * 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
PL238939B1 (pl) * 2016-11-02 2021-10-18 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu Peptyd immunosupresyjny i jego zastosowania
US20220064260A1 (en) * 2018-12-14 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593698A (en) * 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
WO1993020185A1 (en) 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性t細胞は自己免疫を抑制する
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
AU2007266450A1 (en) * 2006-05-31 2007-12-06 The Regents Of The University Of California CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CA3261641A1 (en) * 2013-03-13 2025-06-12 Oncour Pharma, Inc. Immune-modifying particles for the treatment of inflammation

Similar Documents

Publication Publication Date Title
US20250134978A1 (en) Rna cancer vaccines
Shklovskaya et al. MHC class I deficiency in solid tumors and therapeutic strategies to overcome it
O’Keeffe et al. Human dendritic cell subsets and function in health and disease
AR127116A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
Salvato et al. Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives
RS62612B1 (sr) Postupci za dobijanje jednolančane rnk
JP2017516752A5 (enExample)
JP2017524337A5 (enExample)
JP2014534202A5 (enExample)
CL2019003426A1 (es) Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
JP2013521789A5 (enExample)
Monti et al. Human plasmacytoid dendritic cells and cutaneous melanoma
EP4368705A3 (en) Method for generating t-cells compatible for allogenic transplantation
JP2015510393A5 (enExample)
JP2019512020A5 (enExample)
Lopez-Santalla et al. Improving the efficacy of mesenchymal stem/stromal-based therapy for treatment of inflammatory bowel diseases
Simmons et al. T-cell-based cellular immunotherapy of multiple myeloma: current developments
WO2013130499A1 (en) Compositions and methods for cxcr4 signaling and umbilical cord blood stem cell engraftment
JP2017515795A5 (enExample)
WO2015150492A3 (en) An isolated donor mhc-derived peptide and uses thereof
JP5829517B2 (ja) 不溶性蛋白質及び/又はペプチドの可溶化方法
CN107001418A (zh) 源于hsp70的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
ES2905757T3 (es) Métodos y composiciones para el tratamiento del melanoma
Hsieh et al. A GMCSF and IL7 fusion cytokine leads to functional thymic‐dependent T‐cell regeneration in age‐associated immune deficiency
Chak et al. Unfolding the complexity of exosome–cellular interactions on tumour immunity and their clinical prospects in nasopharyngeal carcinoma